thalidomide has been researched along with Gelineau Syndrome in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Excerpt | Relevance | Reference |
---|---|---|
"Thalidomide is a sedative hypnotic that was widely used in the 1950s but was withdrawn due to its teratogenic properties." | 5.29 | Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. ( Dement, WC; Hishikawa, Y; Kanbayashi, T; Mignot, E; Nishino, S; Tafti, M, 1996) |
"Thalidomide is a sedative hypnotic that was widely used in the 1950s but was withdrawn due to its teratogenic properties." | 1.29 | Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. ( Dement, WC; Hishikawa, Y; Kanbayashi, T; Mignot, E; Nishino, S; Tafti, M, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kanbayashi, T | 2 |
Nishino, S | 2 |
Tafti, M | 2 |
Hishikawa, Y | 2 |
Dement, WC | 2 |
Mignot, E | 2 |
2 other studies available for thalidomide and Gelineau Syndrome
Article | Year |
---|---|
Thalidomide, immune modulation and narcolepsy.
Topics: Cytokines; Humans; Narcolepsy; Neurotransmitter Agents; Thalidomide | 1996 |
Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.
Topics: Animals; Binding, Competitive; Cataplexy; Cerebral Cortex; Dogs; Dose-Response Relationship, Drug; N | 1996 |